SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes

SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder, and its management has evolved from mere glycemic control to multitarget metabolic regulation. Sodium–glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated extensive pleiotropic effects in treating T2DM, and its complications...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qian Wu, Jian Zhang, Fuli Zhang, Dongnan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Endocrinology
Subjects:	SGLT2is metabolic regulation type 2 diabetes cardiovascular protection combination therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1601633/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology
by: Iacob-Daniel Goje, et al.
Published: (2025-05-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01)

Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome
by: Juan Guerrero-Mauvecin, et al.
Published: (2025-06-01)

Is the Impact of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors on Bone Metabolism and Fracture Incidence a Class or Drug Effect? A Narrative Review
by: George I. Lambrou, et al.
Published: (2025-04-01)

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-08-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Severe hyperchloremic metabolic acidosis with SGLT2 inhibitors in patients with urinary diversion
by: Carolina Gomes, et al.
Published: (2025-05-01)

Effectiveness of SGLT2 inhibitors compared to sulphonylureas for long-term glycemic control in type 2 diabetes: A meta-analysis
by: Zhouhong Zhan, et al.
Published: (2025-07-01)

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
by: Abhishek Kansara, et al.
Published: (2022-09-01)

Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study
by: Chang-Yuan Hsu, et al.
Published: (2025-03-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)

Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
by: Ji Yun Lee, et al.
Published: (2025-07-01)

Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
by: M. V. Shestakova, et al.
Published: (2022-01-01)

Development of an Efficient Process for a Key Synthetic Intermediate of the SGLT2 Inhibitor LH-1801
by: Jun Qu, et al.

SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges
by: Taimin Luo, et al.
Published: (2025-07-01)

Position of SGLT2i in prediabetes: A systematic review of literature
by: Kaushik Biswas, et al.
Published: (2025-04-01)

Association between SGLT-2 inhibitors and suicide risk in type 2 diabetes and bipolar: a real-world cohort study
by: En-Wei Chang, et al.
Published: (2025-06-01)

Unveiling the anticancer potential of SGLT-2 inhibitors: mechanisms and prospects in clinical oncology—a narrative review
by: Jiaxin Li, et al.
Published: (2025-06-01)

Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors
by: Kyriaki Vafeidou, et al.
Published: (2025-05-01)

SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
by: Marlena Stielow, et al.
Published: (2025-07-01)

SGLT2 inhibition mitigates intracerebral hemorrhage risk by modulating inflammation
by: Mingsheng Huang, et al.
Published: (2025-05-01)

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study
by: Arif Albulushi, et al.
Published: (2025-07-01)

Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice
by: Gašper Tonin, et al.
Published: (2025-07-01)

Sodium-glucose cotransporter 2 inhibitors in chronic kidney disease: A review of current evidence and clinical implications
by: Abdulrahman Saad Alfaiz
Published: (2025-06-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach: Indonesian Perspective - An Expert Opinion
by: Aida Lydia, et al.
Published: (2023-01-01)

The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
by: Francesca Cinti, et al.
Published: (2025-05-01)

SGLT2 Inhibitors and genital infections: a prospective observational study in a tertiary care hospital
by: Numan Malik, et al.
Published: (2025-07-01)

Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
by: Tarunveer S. Ahluwalia, et al.
Published: (2024-02-01)

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence
by: Ruggero Mazzotta, et al.
Published: (2025-08-01)

Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure
by: Eva Muja, et al.
Published: (2025-07-01)

EVALUAREA EFICACITĂȚII TERAPIEI CU INHIBITORI SGLT2 LA PACIENȚII CU INSUFICIENȚĂ CARDIACĂ CU FRACȚIE DE EJECȚIE PĂSTRATĂ
by: Tatiana Cotonet, et al.
Published: (2025-03-01)

Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study
by: Abdullahi Ahmed Mohamed, et al.
Published: (2025-08-01)

Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus
by: Haoyi Yang, et al.
Published: (2025-01-01)

The Effect of Frailty on Body Composition and Its Impact on the Use of SGLT-2 Inhibitors and GLP-1RA in Older Persons with Diabetes
by: Alan Sinclair, et al.
Published: (2025-06-01)

Frailty-stratified effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors and GLP-1 receptor agonists on pulmonary outcomes in type 2 diabetes: a nationwide cohort studyResearch in context
by: Lin-Chieh Meng, et al.
Published: (2025-07-01)

SGLT2-inhibition and myocardial infarction size in patients with type 2 diabetes mellitus– Insights from an acute cardiovascular care center
by: Istvan Bojti, et al.
Published: (2025-08-01)